Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection

Phase 4

Completed

• Conditions: Gastric Cancer After D2 Lymph Node Dissection
• Interventions: Drug: Somatostatin

• Registration Number: NCT01914692
• Lead Sponsor: First Affiliated Hospital, Sun Yat-Sen University

Brief Summary

Gastric cancer radical surgery related complications are common.Somatostatin is a conventional medical therapy for bleeding.This study explore the effect of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node dissection.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-01
• Status Verified: 2013-07
• Primary Completion: 2013-07
• Study Completion: 2013-07
• Study First Submitted: 2013-07-30
• Study First Submitted QC: 2013-07-31
• Last Update Submitted: 2013-07-31
• Study First Posted: 2013-08-02
• Last Update Posted: 2013-08-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

1. More than eighteen years old
2. Gastric cancer diagnosed by pathological examination
3. Be given informed consent
4. Without diabetes/hyperthyroidism/Damages of functions of heart, liver and kidney/Systemic Infection/immunodeficiency

Exclusion Criteria

1. Contraindication of vascular puncture operation
2. Patients who refused to take part in the programe
3. Poor compliance of treatment
4. Malnutrition,BMI<18
5. with pancreatectomy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Somatostatin group	Somatostatin	Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.

Primary Outcome Measures

Name	Time	Method
fistula of pancreas	one year	number of patients

Secondary Outcome Measures

Name	Time	Method
amount of bleeding	six months	amount of bleeding after the operation
seroperitoneum	six months	seroperitoneum volum of patients
infection of incisional wound	one year	number of patients